High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Autor: Jiun-Ruey Hu, Ameet Patel, Shi Huang, Yan Ru Su, Kimberly B. Dahlman, Kelsey Tomasek, Yueli Zhang, Richard T. O’Neil, Jamye F. O’Neal, Isik Turker, Douglas B. Johnson, Joe-Elie Salem, Javid J. Moslehi, Olalekan Oluwole

Publikováno v: Clinical Hematology International, Vol 3, Iss 3 (2021)

Retrospective studies suggest that chimeric antigen receptor T-cell (CAR T) therapy may lead to cardiac injury, but this has not been assessed systematically or prospectively. In this prospective study of 40 patients who received CAR T, we systematic

Externí odkaz: https://doaj.org/article/4f83ab1771a6421f820db08b1d7471ae

Supplementary Figure S2 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Autor: Ann Richmond, Anna E. Vilgelm, Douglas B. Johnson, Ana Grau, Mary Hooks, Rondi M. Kauffmann, Mark C. Kelley, Chi Yan, Gregory D. Ayers, Kimberly B. Dahlman, Vijaya Bharti, Caroline A. Nebhan, Rami Nayef Al-Rohil, Jamye F. O'Neal, Holly Crandall, Christopher Andrew Johnson, Emily Murray, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt

Supplementary FigureS2: Response to KRT-232.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e1c504d7d3c4d2636f557e5692ff159
https://doi.org/10.1158/1078-0432.22468088

Data from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

Autor: Ann Richmond, Anna E. Vilgelm, Douglas B. Johnson, Ana Grau, Mary Hooks, Rondi M. Kauffmann, Mark C. Kelley, Chi Yan, Gregory D. Ayers, Kimberly B. Dahlman, Vijaya Bharti, Caroline A. Nebhan, Rami Nayef Al-Rohil, Jamye F. O'Neal, Holly Crandall, Christopher Andrew Johnson, Emily Murray, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt

Purpose:Over 60% of patients with melanoma respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on BRAF mutation status, but no available agents are available f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::878b6ec941e09bff49ae82d864b61c19
https://doi.org/10.1158/1078-0432.c.6526829

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Autor: Ameet Patel, Isik Turker, Shi Huang, Jamye F. O'Neal, Joe-Elie Salem, Douglas B. Johnson, Kimberly B. Dahlman, Yueli Zhang, Olalekan O. Oluwole, Richard T. O’Neil, Yan Ru Su, Kelsey Tomasek, Jiun-Ruey Hu, Javid Moslehi

Publikováno v: Clinical Hematology International
Clinical Hematology International, Atlantis Press International, 2021, 3 (3), pp.96. ⟨10.2991/chi.k.210718.001⟩
Clinical Hematology International, Vol 3, Iss 3 (2021)

International audience; Retrospective studies suggest that chimeric antigen receptor T-cell (CAR T) therapy may lead to cardiac injury, but this has not been assessed systematically or prospectively. In this prospective study of 40 patients who recei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34f19cccfc8aba29db86a65dc5a41637
https://pubmed.ncbi.nlm.nih.gov/34820614

Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model.

Autor: Peila Chen, Jamye F O'Neal, Nancy D Ebelt, Michael A Cantrell, Shreya Mitra, Azadeh Nasrazadani, Tracy L Vandenbroek, Lynn E Heasley, Carla L Van Den Berg

Publikováno v: PLoS ONE, Vol 5, Iss 5, p e10443 (2010)

Oncogenes induce cell proliferation leading to replicative stress, DNA damage and genomic instability. A wide variety of cellular stresses activate c-Jun N-terminal kinase (JNK) proteins, but few studies have directly addressed the roles of JNK isofo

Externí odkaz: https://doaj.org/article/2da32a800fd040dfb976b13b418185dc